{"id":"NCT00631475","sponsor":"Actelion","briefTitle":"Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443","officialTitle":"Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2010-04","completion":"2010-05","firstPosted":"2008-03-07","resultsPosted":"2012-08-03","lastUpdate":"2025-02-04"},"enrollment":128,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Pulmonary Fibrosis"],"interventions":[{"type":"DRUG","name":"Bosentan","otherNames":["Tracleer"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).","primaryOutcome":{"measure":"Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)","timeFrame":"Start of study to end of study, up to 21 months","effectByArm":[{"arm":"Bosentan Treatment","deltaMin":6.4,"sd":4.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":128},"commonTop":["LIVER FUNCTION TEST ABNORMAL","DYSPNOEA","IDIOPATHIC PULMONARY FIBROSIS","OEDEMA PERIPHERAL"]}}